Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLOPAR vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Acne vulgaris,Brucellosis,Cholera,Granuloma inguinale,Listeriosis,Lymphogranuloma venereum,Mycoplasma pneumoniae infection,Psittacosis,Q fever,Rocky Mountain spotted fever,Syphilis (when penicillin contraindicated),Trachoma,Tularemia,Urinary tract infections (caused by susceptible organisms)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
500 mg orally twice daily for 7-14 days.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
4-6 hours in normal renal function; prolonged to 12-24 hours in moderate impairment; up to 48 hours in severe impairment
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Tetracycline is not extensively metabolized; primarily excreted unchanged in urine and feces.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Renal (80-90% unchanged), fecal (10-20%)
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
25-30% bound to albumin
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
0.2-0.3 L/kg (suggests low tissue penetration; primarily extracellular fluid)
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: 60-75%; IM: ~100%
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Cr Cl 30-50 m L/min: 500 mg once daily; Cr Cl 15-29 m L/min: 250 mg once daily; Cr Cl <15 m L/min or on dialysis: 250 mg every 48 hours.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No adjustment required for mild to moderate impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): use with caution; consider reduced dose.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
For children >1 year: 15 mg/kg/day divided every 12 hours, not to exceed 500 mg per dose.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
No specific dose adjustment based on age alone; dose based on renal function. Use minimum effective dose and monitor renal function.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Tetracycline use during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Photosensitivity: exaggerated sunburn reaction may occur.,Hepatotoxicity: rare but can occur, especially in patients with renal impairment.,Renal impairment: may require dose adjustment; avoid in severe renal dysfunction.,Pseudomembranous colitis: Clostridium difficile-associated diarrhea may occur.,Superinfection: overgrowth of nonsusceptible organisms including fungi.,Use in pregnancy: category D; avoid due to risk to fetus.,Use in children <8 years: avoid due to tooth discoloration and bone growth inhibition.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to tetracycline or any component,Pregnancy (last half),Children under 8 years,Severe hepatic or renal impairment
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid dairy products (milk, yogurt, cheese), calcium-fortified foods, and antacids containing calcium, magnesium, or aluminum within 2 hours of taking cyclopar. Iron supplements, zinc, and bismuth subsalicylate also reduce absorption. Take with a full glass of water; avoid concurrent intake of high-iron foods (e.g., spinach, red meat) within 1-2 hours. No significant interaction with alcohol but caution due to potential hepatotoxicity.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Cyclopar (tetracycline) is classified as FDA Pregnancy Category D. Use is contraindicated in the second and third trimesters due to risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Additionally, tetracyclines can cause reversible inhibition of fetal bone growth. Avoid during pregnancy; alternative antibiotics should be selected.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Tetracyclines are excreted into breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.5–1.5. Theoretical risks include dental staining and bone growth inhibition in the nursing infant. However, due to poor oral absorption and binding to milk calcium, systemic exposure is minimal. Use is generally considered compatible with breastfeeding if short-term; caution is advised with prolonged therapy.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No pharmacokinetic data specifically for pregnancy; standard adult dosing may be used if absolutely necessary, but use is discouraged. If unavoidable, monitor serum levels (therapeutic range 5–10 mcg/m L) as pregnancy-induced changes in volume of distribution and renal clearance may alter drug exposure. Dose adjustments should be guided by clinical response and serum levels.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Cyclopar (tetracycline) should be taken on an empty stomach 1 hour before or 2 hours after meals to enhance absorption. Avoid concurrent use with dairy products, antacids, or iron supplements due to chelation. Photosensitivity is common; advise sun protection. Monitor for superinfection, especially C. difficile colitis. Use with caution in renal impairment; adjust dose to avoid nephrotoxicity. Not recommended in children under 8 years or during pregnancy due to bone and teeth discoloration.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take this medication on an empty stomach with a full glass of water, at least 1 hour before or 2 hours after meals.,Avoid dairy products, antacids, iron supplements, and calcium-rich foods for at least 2 hours before and after taking this drug.,This drug can make your skin more sensitive to sunlight; use sunscreen, wear protective clothing, and avoid tanning beds.,Complete the full course of treatment even if you feel better; do not skip doses.,Inform your doctor if you experience severe diarrhea, vaginal itching, or oral thrush as these may indicate a secondary infection.,Do not use this medication if you are pregnant, planning to become pregnant, or breastfeeding without consulting your doctor.,Store at room temperature away from moisture and heat. Do not use outdated tetracycline as it can become toxic.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLOPAR vs ALFENTA, answered by our medical review team.
CYCLOPAR is a Muscle Relaxant that works by Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLOPAR and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLOPAR is: 500 mg orally twice daily for 7-14 days.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLOPAR and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLOPAR is classified as Category C. Cyclopar (tetracycline) is classified as FDA Pregnancy Category D. Use is contraindicated in the second and third trimesters due to risk of permanent tooth discoloration (yellow-gr. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.